Clinical Site Selection Feasibility Checklist: FDA and ICH E6(R3) Criteria to Prevent Delays and Compliance Risk

Selecting the right clinical trial sites can make or break a study timeline. Poor site selection leads to enrollment delays, protocol deviations, and costly study extensions. According to the 2025 FDA guidance on Good Clinical Practice (E6(R3)), inadequate site evaluation remains one of the top causes of trial delays and regulatory findings.

The latest FDA and ICH guidelines provide clear frameworks for evaluating clinical sites before study initiation. This comprehensive checklist ensures sponsors meet regulatory expectations while building a foundation for successful trial execution. Understanding these requirements helps both sponsors and sites prepare for rigorous feasibility assessments.

Understanding FDA and ICH Site Selection Requirements

The regulatory landscape for clinical site selection centers on two primary documents: FDA’s E6(R3) Good Clinical Practice guidance and ICH E8(R1) General Considerations for Clinical Studies. These guidelines establish the foundation for evaluating site readiness and capability.

Core Regulatory Principles for Site Selection

The FDA’s E6(R3) guidance emphasizes that sponsors must ensure selected sites can properly conduct the study according to Good Clinical Practice (GCP) standards. This means evaluating not just patient populations, but the entire site infrastructure.

Key regulatory principles include:

• Participant protection - Sites must demonstrate adequate safety oversight
• Data integrity - Systems must support reliable data collection and management
• Protocol compliance - Sites need proven ability to follow complex procedures
• Quality assurance - Ongoing monitoring and oversight capabilities must exist

ICH E8(R1) Quality by Design Framework

ICH E8(R1) introduces the concept of Critical-to-Quality factors that must be assessed during site selection. These factors directly impact study success and regulatory compliance.

The guidance recommends identifying risks early and building quality into site selection rather than trying to monitor quality problems later. This proactive approach reduces costly protocol deviations and data issues.

Investigator and Research Team Assessment

Site feasibility begins with evaluating the principal investigator and research team. The FDA requires thorough assessment of investigator qualifications and site staffing adequacy.

Principal Investigator Qualifications

Medical expertise and therapeutic area experience form the foundation of investigator assessment. According to FDA E6(R3), investigators must demonstrate both general clinical research competence and specific knowledge of the study indication.

Essential qualifications include:

• Board certification in relevant specialty
• Previous clinical trial experience in similar therapeutic areas
• Current medical licensure and hospital privileges
• No significant regulatory violations or warning letters
• Adequate time availability for study conduct

Research Team Capability Assessment

Beyond the principal investigator, the entire research team requires evaluation. Sub-investigators, coordinators, and support staff all contribute to study quality and compliance.

Key team assessment areas include:

• Coordinator experience - Proven track record with similar study types
• Staffing levels - Adequate personnel for projected workload
• Training records - Current GCP certification and protocol-specific training
• Staff turnover rates - Stability of the research team

Training and Qualification Documentation

The FDA expects sponsors to verify and document all team qualifications. This includes maintaining training records, CV updates, and continuing education documentation throughout the study.

Site Infrastructure and Resources Evaluation

Physical infrastructure and operational resources directly impact a site’s ability to conduct trials safely and effectively. The FDA guidance requires thorough evaluation of site capabilities before study initiation.

Clinical Facilities Assessment

Physical space adequacy represents a fundamental requirement that many sponsors underestimate. Sites need appropriate facilities for study procedures, patient privacy, and regulatory compliance.

Critical facility elements include:

• Adequate space for study visits and procedures
• Private consultation areas for informed consent
• Secure storage for investigational products
• Temperature-controlled storage with monitoring systems
• Emergency medical equipment and procedures

Laboratory and Diagnostic Capabilities

Laboratory services require special attention during feasibility assessment. Sites must demonstrate both local laboratory certification and ability to handle specialized study requirements.

Laboratory assessment checklist:

• CLIA certification or equivalent local accreditation
• Normal value ranges established for the patient population
• Specimen processing and shipping capabilities
• Backup laboratory arrangements for emergencies
• Quality assurance programs and proficiency testing

Technology and Data Management Systems

Modern clinical trials demand sophisticated technology infrastructure. Sites must demonstrate adequate electronic data capture (EDC) capabilities and IT support.

Technology requirements include:

• Reliable internet connectivity and backup systems
• Computer hardware adequate for EDC systems
• IT support for troubleshooting and maintenance
• Data backup and security procedures
• Electronic signature capabilities when required

Patient Population and Recruitment Assessment

Patient recruitment remains the most common cause of clinical trial delays. Thorough population assessment during feasibility prevents unrealistic enrollment projections and timeline extensions.

Target Population Availability

Patient database analysis provides the most reliable predictor of recruitment success. Sites should demonstrate access to adequate numbers of potential participants through medical records review.

Population assessment should include:

• Historical patient volumes in target indication
• Current patient database size meeting inclusion criteria
• Seasonal variations in patient availability
• Competing studies that might impact recruitment
• Physician referral patterns and relationships

Enrollment Feasibility and Timelines

Realistic enrollment projections require careful analysis of screening ratios and conversion rates. Many sites overestimate their enrollment capabilities, leading to study delays.

Key enrollment metrics include:

• Screen failure rates from similar previous studies
• Time from screening to randomization
• Patient retention rates through study completion
• Seasonal factors affecting patient availability
• Marketing and recruitment strategies planned

Retention and Follow-up Capabilities

Long-term studies require special attention to patient retention strategies. Sites must demonstrate proven ability to maintain participant engagement throughout extended follow-up periods.

Retention assessment factors:

• Historical retention rates in similar studies
• Patient population characteristics affecting retention
• Follow-up procedures and reminder systems
• Transportation assistance or other support services
• Strategies for maintaining contact with participants

Regulatory Compliance and Quality Oversight

FDA inspections focus heavily on site compliance with GCP requirements and quality management systems. Thorough compliance assessment during feasibility prevents regulatory findings later.

GCP Compliance History

Previous FDA inspection results provide the clearest indicator of site compliance capabilities. Sponsors must review inspection history and current compliance status.

Compliance assessment includes:

• FDA inspection history and any warning letters
• Resolution of previous regulatory findings
• Internal audit results and corrective actions
• Standard operating procedures (SOPs) current and adequate
• Quality assurance program implementation

Ethics Committee and IRB Capabilities

Institutional Review Board (IRB) approval represents a critical path item for study startup. Sites must demonstrate efficient IRB processes and reasonable approval timelines.

IRB assessment factors:

• IRB approval timelines for similar studies
• IRB meeting frequency and submission deadlines
• Experience with study type and therapeutic area
• Amendment processing efficiency
• Communication processes with research teams

Documentation and Record Keeping Systems

The FDA requires comprehensive documentation of all trial activities. Sites must demonstrate adequate record keeping systems and document retention capabilities.

Documentation requirements include:

• Source document identification and maintenance
• Regulatory file organization and completeness
• Electronic record systems and data integrity controls
• Archive facilities and long-term storage capabilities
• Document retention policies meeting regulatory requirements

Site Selection Decision Framework and Implementation

Converting feasibility assessment results into site selection decisions requires a structured approach that balances multiple competing factors while maintaining regulatory compliance.

Risk Assessment and Mitigation Strategies

Risk-based site selection aligns with ICH E8(R1) quality by design principles. Sites should be evaluated not just on capabilities, but on risks to study success and mitigation strategies.

Risk assessment categories include:

• High-risk factors - Previous regulatory findings, staff turnover, competing studies
• Medium-risk factors - Limited therapeutic area experience, new technology implementation
• Low-risk factors - Established sites with proven track records
• Mitigation strategies - Additional training, increased monitoring, backup plans

Site Selection Scoring and Ranking

Objective scoring systems help standardize site selection decisions across multiple evaluators and therapeutic areas. Weighted scoring approaches allow prioritization of factors most critical to study success.

Common scoring categories:

• Investigator qualifications (20-25% weight)
• Patient population access (25-30% weight)
• Infrastructure and resources (20-25% weight)
• Regulatory compliance history (15-20% weight)
• Geographic considerations (5-10% weight)

Implementation and Ongoing Assessment

Site selection continues throughout the trial lifecycle. Ongoing performance monitoring ensures selected sites maintain their feasibility assessment capabilities.

Implementation considerations include:

• Site initiation visit planning and execution
• Performance metrics tracking from study start
• Corrective action protocols for underperforming sites
• Site replacement strategies when needed
• Lessons learned documentation for future studies

Conclusion

Effective clinical site selection requires systematic evaluation of investigator qualifications, infrastructure capabilities, patient populations, and regulatory compliance history. The FDA’s E6(R3) and ICH E8(R1) guidelines provide clear frameworks for conducting thorough feasibility assessments that prevent common trial delays and compliance issues.

Success depends on moving beyond simple patient count estimates to comprehensive assessment of all factors affecting study quality and timeline. Sites that demonstrate strong performance across all evaluation categories consistently deliver better enrollment, data quality, and regulatory outcomes.

The investment in thorough feasibility assessment pays dividends throughout the trial lifecycle through reduced monitoring burden, faster enrollment, and smoother regulatory interactions.

Sources

1. E6(R3) Good Clinical Practice Guidance for Industry - FDA’s comprehensive GCP guidelines including site selection requirements
2. E8(R1) General Considerations for Clinical Studies - FDA guidance on clinical study design and quality management
3. ICH E8(R1) General Considerations for Clinical Studies - International harmonized guidelines for clinical study conduct
4. A Framework for Assessing Clinical Trial Site Readiness - Research on site readiness assessment frameworks
5. Clinical Trials Guidance Documents - FDA’s comprehensive clinical trials guidance repository